Servier is an international and independent pharmaceutical company governed by a non-profit foundation, with headquarters in France. It reinvests 25% of its total revenue into R&D, and all profits are used for further development.
Oncology has become a top priority in recent years and the group devotes 37% of its R&D investments to fighting cancer and addressing critical unmet patient’s needs. The long-term strategy of Servier is to focus its research on apoptosis and immuno-oncology.
CellGenix is a leading global supplier of high quality raw materials for the expanding cell and gene therapy space. We develop, manufacture and market human cytokines and growth factors in preclinical and GMP quality along with GMP serum-free media for further manufacturing of ATMPs. We offer our products in combination with expert regulatory and technical support to ensure a seamless transition from research to commercialization.
Fresenius Kabi is a leading global health care company that focuses on pharmaceuticals and medical devices used to care for critically and chronically ill patients. We bring over 60 years experience advancing the fields of cell collection and separation with expertise in closed-system processing. We recently launched Lovo, the only cell processing system that washes and concentrates white blood cells using filtration technology, specifically to serve the needs of the cellular therapies community.
Key Biologics provides biological products to the cell therapy industry worldwide. Non-mobilized and G-CSF mobilized MNC collections are performed under proprietary IRB-approved protocols. Three G-CSF schedules are available: 4day/10ug per kg/single collection, 5day/10ug per kg/single collection and 5day/5ug per kg/two collections. Key operates the Spectra, Optia and Amicus devices allowing customers to compare MNC product characteristics that could influence manufacturing of autologous or allogeneic cell-based therapies.
Previously as Panasonic, and now under our new brand name PHCbi, PHC Europe B.V. guarantees quality and reliability for more than 50 years. This longstanding presence in the market means we’ve built valuable relationships with leading pharmaceutical, healthcare and biotechnology partners. Fast delivery, excellent (back-up) service, optimal cell culture results and the most secure storage for your valuable samples are some of the other reasons. This made us a very important player in both the ultra-low temperature and the CO2 – incubator market.
We share your passion for science. Promega is committed to excellence in technologies for cellular therapy programs (e.g., CAR T cells and T cell receptor modifications) as well as immuno-oncology (e.g., LAG-3, TIM-3, ICOS, CD28, ADCC/ADCP and bi-specific mAbs). All assays are based on bright and sensitive firefly or NanoLuc luciferases. Let’s collaborate.